Posts

Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt

Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR

/by
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
arcticnovartis

  • Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented
  • Biomarker data informing use of investigational CAR-T cell therapy rapcabtagene autoleucel (YTB323) in systemic lupus erythematosus also to be presented
  • Data underscore Novartis commitment to advance innovative medicines for complex, difficult-to-treat autoimmune diseases with high unmet need
/by
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
arcticnovartis

  • Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented
  • Biomarker data informing use of investigational CAR-T cell therapy rapcabtagene autoleucel (YTB323) in systemic lupus erythematosus also to be presented
  • Data underscore Novartis commitment to advance innovative medicines for complex, difficult-to-treat autoimmune diseases with high unmet need
/by
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
arcticnovartis

  • Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521

  • Trial showed reduction in annual cumulative steroid dose vs placebo through Week 52; safety profile consistent with known profile of Cosentyx1
/by
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
arcticnovartis

Basel, October 22, 2025 – Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48.00 per Share, in cash, without interest and subject to any applicable withholding.

/by
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
arcticnovartis

  • PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC)1

  • Most patients with mHSPC progress to metastatic castration-resistant prostate cancer, underscoring urgent need for new therapies that can reduce risk of progression in earlier disease settings2,3
/by
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
arcticnovartis

  • After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1
  • Kisqali remains the only CDK4/6 inhibitor demonstrating consistent and clinically meaningful benefit across the broadest population of HR+/HER2- early breast cancer (EBC) patients, including those with node-negative disease1  
/by